DCST2 activators encompass a range of chemical compounds that engage distinct cellular signaling pathways, ultimately amplifying the functional activity of DCST2. For instance, Phorbol 12-myristate 13-acetate (PMA) and Bisindolylmaleimide I function through the modulation of PKC activity, with PMA activating and Bisindolylmaleimide I inhibiting this kinase. The activation of PKC by PMA could result in the phosphorylation of DCST2 or associated proteins within its signaling pathways, thereby enhancing its activity. Conversely, Bisindolylmaleimide I may disrupt PKC-mediated inhibition on DCST2 pathways, leading to an upsurge in DCST2's functional role. Similarly, the cAMP pathway activators, Forskolin, 8-Bromo-cAMP, and Dibutyryl cAMP (db-cAMP), initiate a cascade via adenylate cyclase or directly activate PKA, which could phosphorylate regulatory proteins linked to DCST2. Increased intracellular calcium levels induced by Ionomycin could activate calcium-dependent kinases that might interact with DCST2, enhancing its activity within the cell.
The influence of hormonal and growth factor signaling is evident in the activation of DCST2 by EGF and Insulin. EGF, through the MAPK/ERK pathway, and Insulin, via the PI3K/Akt pathway, could both potentiate DCST2 activity if it is integrated within these signaling networks. The strategic inhibition by LY294002 suggests that blocking PI3K might shift the balance of cellular signaling, redirecting activation towards DCST2-linked pathways. Additionally, the dynamics of cellular phosphorylation states, modulated by compounds like Calyculin A, which inhibits protein phosphatases, could lead to a net increase in the phosphorylated form of proteins, potentially including DCST2 or its regulators, thereby enhancing its activity. The careful orchestration of intracellular signals by these activators highlights their pivotal role in the fine-tuning of DCST2's activity, without directly increasing its expression or requiring direct binding to the protein, ensuring a more nuanced control over its functional state within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is known to activate Protein Kinase C (PKC), which can lead to the phosphorylation of target proteins involved in various signaling pathways. If DCST2 is a substrate or is associated with pathways regulated by PKC, PMA could enhance its functional activity through this phosphorylation cascade. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing intracellular cAMP levels. This elevation of cAMP can activate PKA, which may phosphorylate proteins in the pathway involving DCST2, leading to its enhanced activity. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate calcium-dependent kinases, such as calmodulin-dependent kinase (CaMK), which may indirectly enhance DCST2 activity if it is regulated by calcium signaling. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid acts through its nuclear receptors to modulate gene expression. If DCST2 is involved in a pathway that is under the transcriptional control of retinoic acid-sensitive genes, its activity could be enhanced by this compound. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
As a cAMP analog, 8-Bromo-cAMP can activate PKA directly, bypassing the need for adenylate cyclase activation. If DCST2 activity is modulated by PKA, then 8-Bromo-cAMP could enhance its activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is another cAMP analog that activates PKA. Similar to 8-Bromo-cAMP, if DCST2 is part of a PKA-regulated pathway, db-cAMP could enhance its activity. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin triggers the PI3K/Akt signaling pathway, which has widespread effects on metabolism, growth, and cell survival. If DCST2 is implicated in pathways downstream of Akt, insulin could enhance its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which could lead to a compensatory activation of alternative pathways that might enhance the activity of DCST2 if it is part of such alternative pathways. | ||||||
(±)-S-Nitroso-N-acetylpenicillamine | 79032-48-7 | sc-200319B sc-200319 sc-200319A | 10 mg 20 mg 100 mg | $74.00 $114.00 $374.00 | 18 | |
SNAP releases nitric oxide (NO) which can activate guanylate cyclase and increase cGMP levels, potentially affecting signaling pathways involving DCST2. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
As an inhibitor of PKC, Bisindolylmaleimide I could disrupt PKC-mediated negative feedback loops, possibly leading to the enhanced activity of pathways where DCST2 is active. | ||||||